MDM2 is a useful prognostic biomarker for resectable gastric cancer

Cancer Science

Volumn 104, Issue 5, 2013, Pages 590-598

  Ye, Yang ^a   Li, Xuan ^a   Yang, Jingjing ^a   Miao, Shuhan ^a   Wang, Shouyu ^a   Chen, Yansu ^a   Xia, Xiaowei ^a   Wu, Xuming ^a,b   Zhang, Jianbing ^a,b   Zhou, Yan ^c   He, Song ^b   Tan, Yongfei ^c   Qiang, Fulin ^b   Li, Gang ^d   Røe, Oluf Dimitri ^e,f   Zhou, Jianwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nantong Cancer Hospital   (China)

^c YIXING PEOPLE S HOSPITAL   (China)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f Levanger Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PROTEIN MDM2; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GASTRECTOMY; GENE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JWA GENE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER; TISSUE MICROARRAY; TREATMENT OUTCOME; UPREGULATION;

AGED; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; FLUOROURACIL; HEAT-SHOCK PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUCOVORIN; MALE; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84876413303     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12111     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Nabeya Y, Suzuki T, Furuya A et al. Calpain regulates thymidylate synthase-5-fluoro-dUMP complex levels associated with response to 5-fluorouracil in gastric cancer cells. Cancer Sci 2011; 102: 1509-15.
3. Vousden KH. p53: death star. Cell 2000; 103: 691-4.
4. Jin S, Levine AJ. The p53 functional circuit. J Cell Sci 2001; 114: 4139-40.
5. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003; 13: 49-58.
6. Schoniger-Hekele M, Hanel S, Wrba F, Muller C. Hepatocellular carcinoma-survival and clinical characteristics in relation to various histologic molecular markers in Western patients. Liver Int 2005; 25: 62-9.
7. Bond GL, Hu W, Bond EE et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
8. Chen H, Ma X, Li Z et al. Functionalization of single-walled carbon nanotubes enables efficient intracellular delivery of siRNA targeting MDM2 to inhibit breast cancer cells growth. Biomed Pharmacother 2012; 66: 334-8.
9. Fang F, Yu XJ, Yu L, Yao L. MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol 2011; 28: 981-5.
10. Li G, Zhai X, Zhang Z, Chamberlain RM, Spitz MR, Wei Q. MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis 2006; 27: 2028-33.
11. Ohmiya N, Taguchi A, Mabuchi N et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006; 24: 4434-40.
12. Chrisanthar R, Knappskog S, Lokkevik E et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS ONE 2011; 6: e19249.
13. Terry K, McGrath M, Lee IM, Buring J, De Vivo I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 983-6.
14. Endo K, Ueda T, Ohta T, Terada T. Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma. Liver 2000; 20: 209-15.
15. Iwakuma T, Lozano G. MDM2, an introduction. Mol Cancer Res 2003; 1: 993-1000.
16. Chen H, Bai J, Ye J et al. JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. Cell Signal 2007; 19: 1315-27.
17. Bai J, Zhang J, Wu J et al. JWA regulates melanoma metastasis by integrin alphaVbeta3 signaling. Oncogene 2010; 29: 1227-37.
18. Tang WY, Wang L, Li C et al. Identification and functional characterization of JWA polymorphisms and their association with risk of gastric cancer and esophageal squamous cell carcinoma in a Chinese population. J Toxicol Environ Health A 2007; 70: 885-94.
19. Wang S, Wu X, Chen Y et al. Prognostic and predictive role of JWA and XRCC1 expressions in gastric cancer. Clin Cancer Res 2012; 18: 2987-96.
20. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
21. Aiko T, Sasako M. The new Japanese Classification of Gastric Carcinoma: points to be revised. Gastric Cancer 1998; 1: 25-30.
22. Weichert W, Roske A, Gekeler V et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008; 9: 139-48.
23. Shen L, Xu W, Li A, Ye J, Zhou J. JWA enhances As(2)O(3)-induced tubulin polymerization and apoptosis via p38 in HeLa and MCF-7 cells. Apoptosis 2011; 16: 1177-93.
24. Yang X, Takano Y, Zheng HC. The pathobiological features of gastrointestinal cancers (Review). Oncol Lett 2012; 3: 961-9.
25. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 101: 452-74.
26. Paoletti X, Oba K, Burzykowski T et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-37.
27. Zietz C, Rossle M, Haas C et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998; 153: 1425-33.
28. Yang JY, Zong CS, Xia W et al. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol 2006; 26: 7269-82.
29. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
30. Woynarowski JM, Faivre S, Herzig MC et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58: 920-7.
31. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol 2012; 3: 251-61.